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Abstract
Before the antibiotic era and cardiac surgery, infective endocarditis (IE) was a predomi-
nantly fatal disease. In-hospital mortality persists relatively high despite development in
medical and surgical treatment. Adequate timing and surgical management of the
infected valve help prevent substantially early and late mortality. The surgical approach
of mitral valve endocarditis should be based on extension of the disease and annular
involvement. When the valve and annulus are severely affected, the best option is to
perform a complete excision and mitral valve replacement (MVR). Only if the disease is
limited to the valvular tissue, mitral valve repair is the preferred surgical option.
Keywords: infective endocarditis, epidemiology of infective endocarditis, mitral valve
surgery, mitral valve repair, periannular abscess
1. Introduction
The term infective endocarditis (IE) refers to infection of the endocardial surface of the heart.
Infection may affect heart valves mainly but may occur within a septal defect, in chordae tendi-
nae, or in the mural endocardium. Shunt infections (e.g., arteriovenous shunts, arterioarterial
shunts (patent ductus arteriosus)) or coarctation of the aorta is similar in presentation to IE. The
main site of cardiac involvement is on the line of closure of a valvar surface. Most affected sites
are the atrial side of the atrioventricular valves or on the ventricular surface of the semilunar
valves [1].
Perhaps the most convincing hypothesis for the pathogenesis of IE has been given to Rodbar in
which high velocity flows from a high-pressure source form in an orifice and enter a low-
pressure sink. Bacteria are deposited through Venturi currents beyond the orifice to form vena
contracta creating mechanical erosion and deposition of platelets and thrombin [2].
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Diagnostic criteria for IE were published in 1982 by von Reyn et al. (the Beth Israel Criteria),
but these criteria did not include echocardiographic findings in the case definitions [3]. Includ-
ing the important role of echocardiography in the evaluation of suspected IE, new case
definitions and diagnostic criteria were proposed in 1994 [4], modified in 2000 and broadly
used since then [5]. The usefulness of echocardiography in the diagnosis of IE is clearly known
[6]; transesophageal imaging has superior sensitivity and specificity, is cost-effective, and
should be done when transthoracic approach is negative and the patient has a high clinical
suspicion of IE.
Even though the infected aortic valve is difficult to repair, well-known repair techniques can be
applied to patients with mitral valve endocarditis. Advantages of mitral valve repair compared
with replacement are well established for noninfectious mitral valve disease and include
low perioperative mortality, preserved left ventricular function, no need for long-term anti-
coagulation, less long-term thromboembolic complications, lower risk of IE, freedom from
reoperation, and improved long-term survival [7].
2. Clinical features and diagnostic criteria
Investigators at Duke University modified the terms introduced by Jones (rheumatic fever);
these criteria include major and minor signs and symptoms, echocardiographic findings,
iatrogenic and nosocomial factors (indwelling catheters), and history of IV drug abuse (Table 1)
[5]. The most common clinical manifestation of IE is fever, which can be present in 95–100% of
patients. Fever may present as low grade or spiking following peak of bacteremia. It is
important to draw two sets of blood cultures from different sites in any patient at risk of
having IE who presents with fever of unknown origin for more than 48 h. Once blood cultures
have been obtained, antibiotics should be started until proper identification of causative
organism [8]. When IE is confirmed by echocardiography, surgery, or autopsy, positive blood
cultures are obtained in 95% of cases when two blood specimens are obtained and are positive
in 98% of cases with four blood specimens [9]. However, when dealing with prosthesis valve
endocarditis (PVE), a negative-culture endocarditis can rise to about 10% of cases on most
surgical series [10, 11]. The diagnosis of IE should be investigated in any patient with sepsis of
unknown origin or fever associated with risk factors. Sepsis can present in a variety of forms
and can range from malaise to shock depending on the virulence of the pathogen and the host
immune response [12, 13]. Stroke or systemic embolism can also be present as a complication
of IE. Whenever a patient presents with persistent or unexplained bacteremia, the diagnosis of
IE should be ruled out. S. aureus bacteremia is associated with IE in 25–30% of cases, and all
patients should undergo echocardiography [14, 15]. Risk factors for developing IE include
previous IE, a prosthetic valve or cardiac device and valvular or congenital heart disease,
indwelling intravenous lines, intravenous drug use, immunosuppression, and a recent dental
or surgical procedure. Popular known signs like Osler’s nodes, Janeway lesions, and Roth
spots are rare; their absence does not rule out infective endocarditis. Heart failure, stroke, or
metastatic infection (osteomyelitis, peripheral abscess) are much more common. Routine labo-
ratory tests are usually nonspecific. Admission electrocardiogram is useful since new distur-
bances may suggest paravalvular or myocardial extension of infection [16].
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Definite infective endocarditis
Pathologic criteria
• Microorganisms demonstrated by culture or histologic examination of a vegetation, a vegetation that has
embolized, or an intracardiac abscess specimen
• Pathologic lesions; vegetation or intracardiac abscess confirmed by histologic examination showing active endocarditis
Clinical criteria
• Two major criteria
• One major criterion and three minor criteria
• Five minor criteria
Possible infective endocarditis
• One major criterion and one minor criterion
• Three minor criteria
Rejected
• Firm alternate diagnosis explaining evidence of IE
• Resolution of IE syndrome with antibiotic therapy for ≤4 days
• No pathologic evidence of IE at surgery or autopsy, with antibiotic therapy for ≤4 days
• Does not meet criteria for possible IE, as above
Major criteria
Blood culture positive for IE
• Typical microorganisms consistent with IE from two separate blood cultures: viridans streptococci, Streptococcus
bovis, HACEK group, Staphylococcus aureus
• Community-acquired enterococci, in the absence of a primary focus
• Microorganisms consistent with IE from persistently positive blood cultures, defined as follows:
• At least two positive cultures of blood samples drawn >12 h apart
• All of three or a majority of ≥ four separate cultures of blood (with the first and last samples drawn at least 1 h apart)
• Single positive blood culture for Coxiella burnetii or antiphase I IgG antibody titer >1:800
Evidence of endocardial involvement
• Echocardiogram positive for IE (TEE recommended in patients with prosthetic valves, rated at least “possible IE” by
clinical criteria or complicated IE [paravalvular abscess]; TTE as first test in other patients), defined as follows:
• Oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on
implanted material in the absence of an alternative anatomic explanation
• Abscess
• New partial dehiscence of prosthetic valve
• New valvular regurgitation (worsening or changing of preexisting murmur not sufficient)
Minor criteria
• Predisposition, predisposing heart condition or injection drug use
• Fever, temperature > 38C (100.4F)
• Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage,
conjunctival hemorrhages, and Janeway lesions
• Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, and rheumatoid factor
• Microbiologic evidence: positive blood culture but does not meet a major criterion as noted above* or serologic
evidence of active infection with organism consistent with IE
• Echocardiographic minor criteria eliminated
HACEK, Haemophilus spp., Aggregatibacter spp., Cardiobacterium hominis, Eikenella corrodens, and Kingella spp.; TEE,
transesophageal echocardiography; TTE, transthoracic echocardiography
Modified from Li et al. [5].
Table 1. Definition of infective endocarditis (IE) according to modified Duke criteria.
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Diagnosis of IE includes the sumof clinical findings,microbiological analysis, and imaging results.
A definite diagnosis includes two major modified Duke criteria, one major plus three minor and
five minor criteria [5]. Alternatively the diagnosis can be made by specimen culture or histology
(obtained by surgery or autopsy) of the vegetation or abscess. The physicist must note that Duke
criteria were devised to help in the diagnosis but never to replace the clinical judgment [17].
Infection of the mitral valve and its supporting structures is less frequent than aortic valve
endocarditis but may be more indolent in its course. When S. aureus is the infecting organism,
the mitral valve is more frequently involved ( 40% of cases) followed by the aortic valve in
36% of cases [18]. Echocardiography plays a major role in diagnosis and detection of compli-
cations. A major criterion includes the presence of valvular vegetation or abscess or new
dehiscence of a prosthetic valve [19]. Besides diagnostic, echocardiography also provides
information on the hemodynamic status of the valve lesion and left and right ventricular
function. In native valve endocarditis (NVE), transthoracic echocardiography (TTE) has a
sensitivity of 75% and specificity of >90% for detection of a vegetation. Transesophageal
echocardiography (TEE) has a sensitivity >90% and should be done in a patient with a negative
or equivocal TTE and high clinical likelihood of infective endocarditis [19]. As for abscess,
leaflet perforation or pseudoaneurysm TEE offers better detection than TTE [20, 21]. In patients
with prosthetic valves, the sensitivity of TTE is lower (36–69%), and TEE is more accurate in
detecting complications and cardiac device infections [22, 23].
3. Therapy
The management of patients with IE necessitates a multidisciplinary approach where cardiol-
ogists, cardiac surgeons, and infectious disease specialists are involved. There are no clinical
randomized trials that guide the management decisions nor a level A evidence in international
guides [8, 24].
3.1. Antibiotics
Antibiotics should be started once blood cultures have been acquired; nevertheless if the
patient is stable, the physician could wait until final report is available [25]. Empirical antibiotic
regimens for the native valve endocarditis and prosthetic valve endocarditis are outlined on
definite guidelines by the British Society for Antimicrobial Chemotherapy (Table 2) [25].
Antibiotics can be modified according to culture results, local resistance patterns, virulence,
and the presence or absence of prosthetic material. Because penetration of antibiotics to vege-
tations is difficult, prolonged parenteral antibiotic administration is advisable. Treatment for at
least 4–6 weeks is usually necessary and longer for some cases (e.g., Q fever endocarditis).
3.2. Surgery
About 40–50% of patients with IE undergo surgical therapy [26, 27]. Goals of surgery are
removal of infected tissue and drainage of abscess, restoration of ventriculoarterial or atrio-
ventricular continuity, and reversion to hemodynamic stability. In children, this process may
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require repairing of the underlying malformation. Valve repair and replacement are options
for reconstruction, and there is no evidence that favors a bioprosthetic valve over a mechanical
valve. Heart failure caused by valvular obstruction or regurgitation is the most common indi-
cation for surgery. A dismal prognosis is ensued when refractory pulmonary edema or cardio-
genic shock is present and no emergent surgery is done [28, 29].
There is limited evidence to guide clinical practice when the patient has well-tolerated severe
valve regurgitation and postpone surgery until stabilization with antibiotics. Complex or
uncontrolled infection is the second indication for surgery. The complications include abscess,
pseudoaneurysm, fistula, or atrioventricular block. A pseudoaneurysm is a perivalvular cavity
that communicates with the cardiac chambers (evidenced by Doppler color), whereas an
abscess is a pus-filled perivalvular cavity that does not communicate [19]. If perivalvular
infection progresses, a fistula can be created (usually aorto-cavitary) which can have a mortal-
ity as high as 41% even with surgery [30]. Prevention of embolism is the third indication for
surgery. This complication can affect 25–50% of patients [31]. Stroke is the most common
presentation, but embolism resulting in end-organ infarction (kidney, spleen, coronaries, mes-
entery, and limbs) can also be present. Most emboli occur in the first 2 weeks after diagnosis
with risk decreasing rapidly after antibiotics are instituted [32, 33]. Embolism is more likely
when the vegetation is large (>10 mm), highly mobile, and located in the mitral valve [34].
Persistent or relapsing infection and infection caused by antibiotic-resistant microorganisms (e.g.,
S. aureus, S. lugdunensis, Pseudomonas, fungi) are also indications for surgery [27].
Empirical antibiotic regimen and dose Comment
Native valve endocarditis—indolent
presentation
Amoxicillin (2 g, every 4 h,
intravenously) + gentamicin* (optional;
1 mg/kg of actual bodyweight)
Better activity than benzylpenicillin
against enterococci and many
HACEK bacteria; the use of
gentamicin before availability of
culture results is controversial
Native valve endocarditis— severe
sepsis (without risk factors for
multiresistant enteric Gram-negative
bacilli, Pseudomonas)
Vancomycin* (dose as per local
guidelines) + gentamicin* (1 mg/kg of
ideal bodyweight, every 12 h,
intravenously)
Activity against staphylococci
(including meticillin-resistant
Staphylococcus aureus)
Native valve endocarditis—severe
sepsis (with risk factors for
multiresistant enteric Gram-negative
bacilli, Pseudomonas)
Vancomycin* (dose as per local
guidelines) + meropenem (2 g, every
8 h, intravenously)
Prosthetic valve endocarditis—pending
blood cultures or with negative blood
cultures
Vancomycin* (1 g, every 12 h,
intravenously) + gentamicin* (1 mg/kg,
every 12 h, intravenously) + rifampicin
(300–600 mg, every 12 h, orally or
intravenously)
Adapted from Gould et al. [25].
All antibiotic doses are adjusted according to renal function. HACEK=Haemophilus spp., Aggregatibacter actinomycetem-
comitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kinga.
*Regular measurement of serum concentrations needed to monitor and adjust dosing.
Table 2. Empirical treatment for different clinical scenarios in patients with suspected infective endocarditis.
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Surgery for IE is done through partial or full median sternotomy. Suppurative pericarditis
suggests a previous perforation at the aortic or mitral ring or ring abscess [35, 36]. It is
recommended to use bicaval cannulation to facilitate the procedure in the presence of
burrowing abscess, acquired septal perforation, unexpected right-sided valve involvement,
or complex aortic root reconstruction. Intraoperative TEE plays a major role in diagnosis and
treatment guidance. When left-sided IE is present, minimal manipulation of the heart
is important to avoid migration of embolic material. Ample excision of infected tissue is
performed with drainage of abscess and closure of defects [37]. When mitral endocarditis is
present, aortic valve involvement should be considered. Although absence of echocardio-
graphic anomalies in the aortic area argue against the presence of vegetations and inspection
of the aortic valve is not necessary. Reconstruction on mitral valve area can be accomplished
when the vegetation is healed or small and the tensor apparatus is mostly uncompromised.
Usual sites of native valve endocarditis are drop lesion of anterior leaflet or leaflet vegetation
and ring abscess of posterior portion (Figure 1). Small perforations may be closed using
autologous pericardium or bovine pericardial patch, or otherwise the defect may be closed
using continuous suture (Figure 2). Reconstruction of the mitral valve represents a challenge
if major involvement of the valves is present. Most of the times, a replacement is considered;
nevertheless, the risk for PVE is greater especially in ongoing positive blood cultures. If
commissural areas are compromised by the infection, a sliding annuloplasty can be
performed. Partial leaflet resection, pericardial patch replacement of mid-leaflet areas, or
both may be used [37]. The remaining orifice size after reconstruction must be large enough
(25 mm in an adult, z-score  2 or greater in children) to prevent mitral stenosis [37]. Suture
annuloplasty is preferable over prosthetic ring in active IE, but a biodegradable annuloplasty
ring has been suggested by some authors [38]. In the absence of active IE (e.g., negative
blood cultures, no inflammation), classical reconstruction techniques may be used for the
mitral valve. Quadrangular resection of a portion of the posterior leaflet (Figure 3) or
triangular resection of a portion of the anterior leaflet may be done, followed by the insertion
Figure 1. Drop lesion of anterior leaflet and leaflet vegetation and ring abscess of posterior leaflet.
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Figure 2. Pericardial patch used to close a drop lesion of the anterior leaflet.
Figure 3. Limited quadrangular resection and sliding plasty of posterior leaflet.
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of a partial or complete annular ring. When resecting the mitral valve, the posteroinferior
zone of the mitral annulus should be inspected because myocardial ring abscess usually occurs
in this location [39, 40]. When left atrioventricular discontinuity is present in mitral valve IE, a
small variation of the usual valve replacement can be used. After thorough debridement of the
affected tissue in the mitral ring, interrupted horizontal mattress sutures are anchored with felt
or autologous pericardium pledgets to the ventricular aspect of the mitral annulus, brought up
through the left atrial aspect and then through the prosthetic sewing ring. Deep bytes are
performed [37]. When extensive ring abscess is present (Figure 4), a different approach is done.
The atrioventricular discontinuity is reconstructed using an autologous or bovine pericardial
patch. The ventricular aspect is anchored to the myocardium and endocardium using deep bytes
of continuous 3-0 or 4-0 polypropylene suture. The superior aspect of this patch is anchored to
the left atrial side with a continuous suture (Figure 5). The prosthesis is anchored to the ventric-
ular aspect of the suture line using interrupted horizontal mattress sutures supported with felts
pledgets (Figure 6) [37]. Using antibiotic, antiseptic solutions (e.g., povidone-iodine), or antifun-
gal agents to impregnate the prosthesis and the affected area has been described to help in the
management of this entity [41–43]. Mitral valve repair for IE continues to be challenging and
much less commonly performed than valve replacement [44]. Repairing tissues that may be
infected in the acute stages and the durability of repairing inflamed tissues are the main concerns
influencing the decision [45–47]. Several studies have reported excellent results for mitral valve
repair in IE [48–51].
Figure 4. Infective endocarditis with ring abscess compromising the posterior leaflet of mitral valve.
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4. Results
Hospital mortality for valve operations in patients with IE varies widely (4–30%) [52–57]. This
variation can be due to several factors, especially the difference in risk between the acute phase of IE
and the healed stage. A study from Richardson reported a mortality of 14% in surgically treated
patients versus 44% in those medically treated. Operative mortality was affected by urgency of
operation.Mortality for electiveoperations (next convenientday),was5%, forurgent operations (next
day), 16% and for emergent operations in patientswith cardiogenic shock (immediately), 33% [58].
Figure 5. The defect is covered by a pericardial patch anchored within the left ventricle and extending up across the base
of the posterior leaflet. Stitches then are placed to the left atrial wall.
Figure 6. Prosthesis is placed in position. The posterior suture line is on the patch in this case. Eventually the prosthesis
may be seated below the patch on ventricular wall.
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Freedom from reoperation is higher when the mitral valve is involved (compared with the aortic
valve) probably for less annular involvement. In a series from Brigham and Women’s Hospital
(Boston) reporting freedom from reoperation for mitral valve IE, the results found 92 and 62% at
5 and 10 years for acute endocarditis and 94% and 84% for healed endocarditis (p = 0.7), respec-
tively [59]. A serious complication after valve replacement for IE is a new or worsening neuro-
logic deficit. Friable vegetation may dislodge and cause CNS deficits. Moreover, an existing CNS
deficit is aggravated by operation. A study from university of Illinois found evidence of cerebral
septic emboli in 42% of patients who underwent valve replacement for IE. Complications
included postoperative strokes in 6%, brain abscesses in 2%, and seizures in 1% [60].
5. Indications for operation
Indications for operation are based in the hemodynamic state of the valvar lesion or defect.
When active NVE is present, a lack of consensus exists about some of the specific indications
for surgery [61]. General indications for operation, however, exist from both the American and
European societies (Table 3) [8, 24]. As for timing of surgery, specific recommendations are
outlined in Table 4 [26]. However it is important to remember that no randomized controlled
Congestive heart failure*
• Congestive heart failure caused by severe aortic or mitral regurgitation or, more rarely, by valve obstruction caused
by vegetations
• Severe acute aortic or mitral regurgitation with echocardiographic signs of elevated left ventricular end-diastolic
pressure or significant pulmonary hypertension
• Congestive heart failure as a result of prosthetic dehiscence or obstruction
Periannular extension
• Most patients with abscess formation or fistulous tract formation
Systemic embolism†
• Recurrent emboli despite appropriate antibiotic therapy
• Large vegetations (10 mm) after one or more clinical or silent embolic events after initiation of antibiotic therapy
• Large vegetations and other predictors of a complicated course
• Very large vegetations (15 mm) without embolic complications, especially if valve-sparing surgery is likely (remains
controversial)
Cerebrovascular complications‡
• Silent neurological complication or transient ischemic attack and other surgical indications
• Ischemic stroke and other surgical indications, provided that cerebral hemorrhage has been excluded and neuro-
logical complications are not severe (e.g., coma)
Persistent sepsis
• Fever or positive blood cultures persisting for >5 to 7 days despite an appropriate antibiotic regimen, assuming that
vegetations or other lesions requiring surgery persist and that extracardiac sources of sepsis have been excluded
• Relapsing IE, especially when caused by organisms other than sensitive streptococci or in patients with prosthetic
valves
Difficult organisms
• S. aureus IE involving a prosthetic valve and most cases involving a left-sided native valve
• IE caused by other aggressive organisms (Brucella, Staphylococcus lugdunensis)
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• IE caused by multiresistant organisms (e.g., methicillin-resistant S. aureus or vancomycin-resistant enterococci) and
rare infections caused by Gram-negative bacteria
• Pseudomonas aeruginosa IE
• Fungal IE
• Q fever IE and other relative indications for intervention
Prosthetic valve endocarditis
• Virtually all cases of early prosthetic valve endocarditis
• Virtually all cases of prosthetic valve endocarditis caused by S. aureus
• Late prosthetic valve endocarditis with heart failure caused by prosthetic dehiscence or obstruction or other
indications for surgery
*Surgery should be performed immediately, irrespective of antibiotic therapy, in patients with persistent pulmonary
edema or cardiogenic shock. If congestive heart failure disappears with medical therapy and there are no other surgical
indications, intervention can be postponed to allow a period of days or weeks of antibiotic treatment under careful clinical
and echocardiographic observation. In patients with well-tolerated severe valvular regurgitation or prosthetic dehiscence
and no other reasons for surgery, conservative therapy under careful clinical and echocardiographic observation is
recommended with consideration of deferred surgery after resolution of the infection, depending upon tolerance of the
valve lesion.
†In all cases, surgery for the prevention of embolism must be performed very early since embolic risk is highest during the
first days of therapy.
‡Surgery is contraindicated for at least 1 month after intracranial hemorrhage unless neurosurgical or endovascular
intervention can be performed to reduce bleeding risk.
Adapted from ACC/AHA 2014 Guidelines [8].
Table 3. Indications for surgery for infective endocarditis.
Emergency surgery (within 24 h)
• Native (aortic or mitral) or prosthetic valve endocarditis and severe congestive heart failure or cardiogenic shock
caused by:
• Acute valvular regurgitation
• Severe prosthetic dysfunction (dehiscence or obstruction)
• Fistula into a cardiac chamber or the pericardial space
Urgent surgery (within days)
• Native valve endocarditis with persisting congestive heart failure, signs of poor hemodynamic tolerance, or abscess
• Prosthetic valve endocarditis with persisting congestive heart failure, signs of poor hemodynamic tolerance, or
abscess
• Prosthetic valve endocarditis caused by staphylococci or Gram-negative organisms
• Large vegetation (10 mm) with an embolic event
• Large vegetation (10 mm) with other predictors of a complicated course
• Very large vegetation (15 mm), especially if conservative surgery is available
• Large abscess and/or periannular involvement with uncontrolled infection
Early elective surgery (during the in-hospital stay)
• Severe aortic or mitral regurgitation with congestive heart failure and good response to medical therapy
• Prosthetic valve endocarditis with valvular dehiscence or congestive heart failure and good response to medical
therapy
• Presence of abscess or periannular extension
• Persisting infection when extracardiac focus has been excluded
• Fungal or other infections resistant to medical cure
Adapted from Prendergast et al. [26].
Table 4. Timing of surgery.
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trials are available to guide current practice. Among the indications for surgery in IE, operation
for acute heart failure provides the greatest survival benefit [62, 63].
Infective endocarditis is a serious condition associated with significant morbidity and mortal-
ity. Adequate management requires intervention of multiple specialists. Correct and timed
diagnosis and antibiotics are necessary, but an important percentage of patients still require
surgery. Surgical mortality is high, but long-term results continue to improve with increased
number of patient undergoing valve conserving surgery.
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